CDC NEWS


powered by Surfing Waves


Latest News


What You Need to Know about Variants


27 Nov 2021

Omicron Variant No cases of this variant have been identified in the U.S. to date. CDC is following the details of this new variant. See CDC’s Media Statement.


Coronavirus (COVID-19) Update: FDA Expands Eligibility for COVID-19 Vaccine Boosters


19 Nov 2021

Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUA) for both the Moderna and Pfizer-BioNTech COVID-19 vaccines authorizing use of a single booster dose for all individuals 18 years of age and older after completion of primary vaccination with any FDA-authorized or approved COVID-19 vaccine. The Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices will meet later today to discuss further clinical recommendations.


Moderna COVID-19 booster may protect against variants


03 Nov 2021

At a Glance A booster of the Moderna COVID-19 vaccine increased levels of neutralizing antibodies against all variants of concern in a primate study. The findings suggest that COVID-19 boosters not only lengthen immunity but help broaden and strengthen the immune response.


DC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years


02 Nov 2021

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation that children 5 to 11 years old be vaccinated against COVID-19 with the Pfizer-BioNTech pediatric vaccine. CDC now expands vaccine recommendations to about 28 million children in the United States in this age group and allows providers to begin vaccinating them as soon as possible.


Breakthrough Infections Occur in Those with Lower Antibody Levels, Israeli Study Shows


26 Oct 2021

To see how COVID-19 vaccines are working in the real world, Israel has provided particularly compelling data. The fact that Israel is relatively small, keeps comprehensive medical records, and has a high vaccination rate with a single vaccine (Pfizer) has contributed to its robust data collection. Now, a new Israeli study offers some insight into those relatively uncommon breakthrough infections. It confirms that breakthrough cases, as might be expected, arise most often in individuals with lower levels of neutralizing antibodies.




Articles


Pfizer Vaccine Appears to Work Against Variant, Research Shows


08 Jan 2021

Laboratory experiments indicate the Pfizer/BioNTech vaccine will offer protection against the two coronavirus variants found in the United Kingdom and South Africa.




COVID Likely the Third-Leading Cause of Death in US, CDC Says


07 Jan 2021

COVID-19 was probably the third leading cause of death in the United States during 2020, CNN reported, citing an email from statisticians with the U.S. Centers for Disease Control and Prevention.




Moderna CEO: Vaccine Will Likely Work for 'a Couple of Years'


07 Jan 2021

The Moderna vaccine ― one of two vaccines now being distributed in the United States ― will "potentially" provide protection against COVID-19 for several years, the biotech company's CEO said, according to Reuters.




Over Half of COVID Transmission May Occur via Asymptomatic People


07 Jan 2021

As COVID-19 cases surge and vaccinations lag, health authorities continue to seek additional ways to mitigate the spread of the novel coronavirus.




SARS-CoV-2 Transmission From People Without COVID-19 Symptoms


07 Jan 2021

IMPORTANCE Severeacuterespiratorysyndromecoronavirus2(SARS-CoV-2),theetiologyof coronavirus disease 2019 (COVID-19), is readily transmitted person to person. Optimal control of COVID-19 depends on directing resources and health messaging to mitigation efforts that are most likely to prevent transmission, but the relative importance of such measures has been disputed.




Enroll for Free